From the British Medical Journal (BMJ): A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory panellists who recommended approval.
Brain Shrinkage / Death
